Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| IQV - IQVIA | 4.86% | Add +20.5% | 3,867,112 | $224.77 | $869M | +659,000 | +$231M |
| TRU - Transunion | 4.08% | Add +8.3% | 9,324,793 | $78.33 | $730M | +713,200 | +$195M |
| TMO - Thermo Fisher Scientific | 3.63% | Add +18.5% | 1,243,659 | $521.75 | $649M | +194,600 | +$44M |
| UNH - Unitedhealth Group | 3.38% | Add +45.4% | 1,258,800 | $480.64 | $605M | +392,800 | +$196M |
| EXEL - Exelixis | 2.76% | Add +10.2% | 25,860,000 | $19.11 | $494M | +2,394,000 | +$39M |
| ARMK - Aramark | 2.62% | Reduce −3.1% | 10,886,884 | $43.05 | $469M | −351,000 | +$66M |
| GOOG - Alphabet · CL C | 2.57% | Reduce −30.3% | 3,802,140 | $120.97 | $460M | −1,654,000 | −$107M |
| SPGI - S&P Global | 2.43% | Reduce −5.7% | 1,086,295 | $400.89 | $435M | −65,605 | +$38M |
| AZNN — | 2.42% | Add +3.3% | 6,059,553 | $71.57 | $434M | +192,000 | +$26M |
| CRM - Salesforce | 2.30% | Reduce −44.5% | 1,944,338 | $211.26 | $411M | −1,557,500 | −$289M |
| ADI - Analog Devices | 2.26% | New | 2,075,000 | $194.81 | $404M | +2,075,000 | +$404M |
| SHW - Sherwin Williams | 2.04% | Add +5.2% | 1,375,392 | $265.52 | $365M | +68,600 | +$71M |
| WAB - Wabtec | 1.99% | Add +13.4% | 3,241,930 | $109.67 | $356M | +384,000 | +$67M |
| CNC - Centene Del | 1.78% | Reduce −1.0% | 4,729,075 | $67.45 | $319M | −45,700 | +$17M |
| INTU - Intuit | 1.77% | Reduce −24.1% | 691,300 | $458.19 | $317M | −219,700 | −$89M |
| NYT - New York Times · CL A | 1.75% | Add +25.3% | 7,964,791 | $39.38 | $314M | +1,610,000 | +$67M |
| MA - Mastercard · CL A | 1.72% | Add +8.0% | 784,771 | $393.30 | $309M | +58,300 | +$45M |
| MSFT - Microsoft | 1.64% | Reduce −48.4% | 861,178 | $340.54 | $293M | −806,300 | −$187M |
| HWM - Howmet Aerospace | 1.62% | Reduce −15.6% | 5,857,627 | $49.56 | $290M | −1,083,900 | −$4M |
| AON - AON PLC · CL A | 1.60% | Add +2.9% | 827,786 | $345.20 | $286M | +23,100 | +$32M |
| YMM - Full Truck Alliance | 1.59% | Add +4.7% | 45,858,238 | $6.22 | $285M | +2,053,000 | −$48M |
| BX - Blackstone | 1.59% | Reduce −2.6% | 3,058,251 | $92.97 | $284M | −81,700 | +$9M |
| NOW - Servicenow | 1.56% | Reduce −29.0% | 497,050 | $561.97 | $279M | −202,600 | −$46M |
| BSX - Boston Scientific | 1.52% | Reduce −34.5% | 5,045,257 | $54.09 | $273M | −2,660,000 | −$113M |
| EFX - Equifax | 1.39% | Reduce −24.2% | 1,058,697 | $235.30 | $249M | −337,900 | −$34M |
| V - VISA · CL A | 1.38% | Add +3.0% | 1,039,310 | $237.48 | $247M | +29,900 | +$19M |
| CSGP - Costar Group | 1.37% | Reduce −19.4% | 2,751,056 | $89.00 | $245M | −660,129 | +$10M |
| XYZ - Block · CL A | 1.24% | Add +16.9% | 3,344,050 | $66.57 | $223M | +483,000 | +$26M |
| ELV - Elevance Health | 1.11% | Reduce −33.9% | 445,330 | $444.29 | $198M | −228,300 | −$112M |
| BIIB - Biogen | 0.96% | Reduce −2.5% | 604,098 | $284.85 | $172M | −15,700 | −$245K |
| BABA - Alibaba Group | 0.87% | Add +3.9% | 1,870,000 | $83.35 | $156M | +70,000 | −$28M |
| Sarepta Therapeutics | 0.77% | Add +32.0% | 1,205,200 | $114.52 | $138M | +291,900 | +$12M |
| PTGX - Protagonist Therapeutics | 0.70% | Add +72.5% | 4,511,430 | $27.62 | $125M | +1,896,416 | +$64M |
| HUM - Humana | 0.65% | Add +5.6% | 258,461 | $447.13 | $116M | +13,800 | −$3M |
| LNTH - Lantheus | 0.64% | Add +639.4% | 1,360,500 | $83.92 | $114M | +1,176,500 | +$99M |
| PACB — | 0.62% | Add +31.2% | 8,338,120 | $13.30 | $111M | +1,983,000 | +$37M |
| BEAM - Beam Therapeutics | 0.61% | Add +0.3% | 3,441,522 | $31.93 | $110M | +9,601 | +$5M |
| INSP - Inspire Med Sys | 0.59% | Add +33.2% | 323,096 | $324.64 | $105M | +80,500 | +$48M |
| Iveric Bio | 0.54% | Add +403.8% | 2,442,299 | $39.34 | $96M | +1,957,500 | +$84M |
| PCG - Pg And E | 0.48% | Hold | 5,005,142 | $17.28 | $86M | — | — |
| HCA - Hca Healthcare | 0.45% | Add +67.6% | 262,400 | $303.48 | $80M | +105,800 | +$38M |
| AGIO - Agios Pharmaceuticals | 0.43% | Add +28.5% | 2,688,829 | $28.32 | $76M | +596,000 | +$28M |
| RVMD - Revolution Medicines | 0.42% | Reduce −15.2% | 2,783,480 | $26.75 | $74M | −500,120 | +$3M |
| BEKE - KE | 0.39% | Hold | 4,758,500 | $14.85 | $71M | — | — |
| OPCH - Option Care Health | 0.38% | New | 2,067,134 | $32.49 | $67M | +2,067,134 | +$67M |
| NTRA - Natera | 0.36% | Add +100.1% | 1,324,183 | $48.66 | $64M | +662,400 | +$28M |
| ARGX - Argenx Se | 0.35% | New | 161,000 | $389.73 | $63M | +161,000 | +$63M |
| THC - Tenet Healthcare | 0.34% | Add +93.3% | 752,000 | $81.38 | $61M | +363,000 | +$38M |
| CI - The Cigna Group | 0.34% | New | 218,000 | $280.60 | $61M | +218,000 | +$61M |
| Masimo | 0.34% | Reduce −41.8% | 367,649 | $164.55 | $60M | −264,000 | −$56M |
| Chinook Therapeutics | 0.33% | New | 1,523,000 | $38.42 | $59M | +1,523,000 | +$59M |
| EVH - Evolent Health · CL A | 0.32% | Add +66.2% | 1,900,909 | $30.30 | $58M | +757,000 | +$20M |
| Exact Sciences | 0.32% | New | 602,000 | $93.90 | $57M | +602,000 | +$57M |
| Aerojet Rocketdyne | 0.29% | New | 959,378 | $54.87 | $53M | +959,378 | +$53M |
| Reata Pharmaceuticals · CL A | 0.26% | Add +39.0% | 451,700 | $101.96 | $46M | +126,700 | +$17M |
| UTHR - United Therapeutics | 0.24% | Reduce −70.9% | 193,267 | $220.75 | $43M | −471,500 | −$106M |
| ENTA - Enanta Pharmaceuticals | 0.22% | Add +21.0% | 1,875,000 | $21.40 | $40M | +325,000 | −$23M |
| Ambrx Biopharma | 0.21% | Add +528.5% | 2,269,000 | $16.46 | $37M | +1,908,000 | +$34M |
| Savara | 0.19% | Hold | 10,908,086 | $3.20 | $35M | — | — |
| Lufax · CL A | 0.16% | Reduce −47.9% | 19,949,819 | $1.43 | $29M | −18,346,724 | −$50M |
| ROIV - Roivant Sciences | 0.13% | New | 2,355,000 | $10.08 | $24M | +2,355,000 | +$24M |
| AIG - American Eqty Invt Life Hld | 0.11% | New | 383,000 | $52.11 | $20M | +383,000 | +$20M |
| AXSM - Axsome Therapeutics | 0.11% | New | 272,800 | $71.86 | $20M | +272,800 | +$20M |
| Sdcl Edge Acquisition · CL A | 0.10% | Hold | 1,732,500 | $10.44 | $18M | — | — |
| BHVN - Biohaven | 0.10% | Hold | 750,000 | $23.92 | $18M | — | — |
| Zymeworks | 0.10% | Hold | 2,000,000 | $8.64 | $17M | — | — |
| Ares Acquisition · CL A | 0.08% | Hold | 1,425,000 | $10.57 | $15M | — | — |
| VYGR - Voyager Therapeutics | 0.08% | Add +62.1% | 1,292,000 | $11.45 | $15M | +495,000 | +$9M |
| Life Storage | 0.07% | New | 89,794 | $132.96 | $12M | +89,794 | +$12M |
| COGT - Cogent Biosciences | 0.07% | Hold | 983,452 | $11.84 | $12M | — | — |
| BRKR - Bruker | 0.06% | Reduce −69.6% | 150,476 | $73.92 | $11M | −344,000 | −$28M |
| Screaming Eagle Acquisitn · CLASS A | 0.06% | Hold | 1,000,000 | $10.33 | $10M | — | — |
| R1 Rcm | 0.06% | New | 552,000 | $18.45 | $10M | +552,000 | +$10M |
| RIO - Rio Tinto | 0.05% | Hold | 137,500 | $63.84 | $9M | — | — |
| Holding · CL A | 0.05% | Hold | 775,200 | $10.56 | $8M | — | — |
| Holding · CLASS A | 0.04% | Hold | 745,000 | $10.35 | $8M | — | — |
| Holding | 0.04% | Reduce −35.9% | 1,000,000 | $7.34 | $7M | −560,500 | +$2M |
| Corsair Partnering · CL A | 0.04% | Hold | 700,000 | $10.36 | $7M | — | — |
| EHC - Encompass Health | 0.04% | New | 100,000 | $67.71 | $7M | +100,000 | +$7M |
| SLAM · CL A | 0.03% | Hold | 570,396 | $10.69 | $6M | — | — |
| Blue Whale Acquisition · CLASS A | 0.03% | Hold | 575,000 | $10.16 | $6M | — | — |
| VNET - VNET Group | 0.03% | Hold | 1,775,000 | $2.90 | $5M | — | — |
| Gores Ix · CLASS A | 0.03% | Hold | 500,000 | $10.25 | $5M | — | — |
| INTC - Intellia Therapeutics | 0.03% | New | 116,000 | $40.78 | $5M | +116,000 | +$5M |
| Cara Therapeutics | 0.03% | Reduce −16.5% | 1,666,591 | $2.83 | $5M | −328,779 | −$5M |
| Forest Road Acquisition Cor · CL A | 0.02% | Hold | 400,000 | $10.25 | $4M | — | — |
| Finserv Acquisition Ii · CL A | 0.02% | Hold | 400,000 | $10.23 | $4M | — | — |
| Cartica Acquisition · CLASS A | 0.02% | Hold | 350,000 | $10.67 | $4M | — | — |
| APLSUSD - Apellis Pharmaceuticals | 0.02% | Reduce −87.4% | 40,053 | $91.10 | $4M | −277,500 | −$17M |
| Uta Acquisition · CLASS A | 0.02% | Hold | 344,100 | $10.57 | $4M | — | — |
| ALVO - Alvotech | 0.02% | Reduce −12.6% | 437,110 | $7.74 | $3M | −62,890 | −$3M |
| Swiftmerge Acquisition · CLASS A | 0.02% | Reduce −84.8% | 300,000 | $10.34 | $3M | −1,680,000 | −$17M |
| Berenson Acquisition I · CL A | 0.02% | Reduce −88.5% | 285,715 | $10.27 | $3M | −2,189,285 | −$22M |
| Atento S A | 0.01% | Hold | 2,230,357 | $1.00 | $2M | — | — |
| Arya Sciences Acqu Iv · CL A | 0.01% | Hold | 200,000 | $10.64 | $2M | — | — |
| PRVA - Privia Health Group | 0.01% | New | 74,000 | $26.11 | $2M | +74,000 | +$2M |
| Marblegate Acquisition · CL A | 0.01% | Hold | 150,000 | $10.38 | $2M | — | — |
| ICE - Intercontinental Exchange | 0.01% | Reduce −75.3% | 12,786 | $113.08 | $1M | −39,046 | −$4M |
| Blueprint Medicines | 0.01% | Hold | 22,420 | $63.20 | $1M | — | — |
| OKLO - Altc Acquisition · CL A | 0.01% | Hold | 98,300 | $10.43 | $1M | — | — |
| Summit Midstream Partners | 0.01% | Hold | 58,214 | $16.25 | $946K | — | — |
| Avrobio | 0.00% | Reduce −71.1% | 899,700 | $0.9501 | $855K | −2,216,300 | −$2M |
| MDGL - Madrigal Pharmaceuticals | 0.00% | Reduce −98.0% | 3,319 | $231.00 | $767K | −160,500 | −$39M |
| CYTK - Cytokinetics | 0.00% | Reduce −97.7% | 21,772 | $32.62 | $710K | −916,300 | −$32M |
| EDU — | 0.00% | Hold | 13,000 | $39.49 | $513K | — | — |
| Karuna Therapeutics | 0.00% | Hold | 2,200 | $216.85 | $477K | — | — |
| BNTX - Biontech Se | 0.00% | Reduce −97.2% | 3,844 | $107.93 | $415K | −133,800 | −$17M |
| ALNY - Alnylam Pharmaceuticals | 0.00% | Reduce −70.2% | 2,000 | $189.94 | $380K | −4,719 | −$966K |
| Better Therapeutics | 0.00% | Reduce −52.7% | 330,619 | $1.08 | $357K | −368,423 | −$152K |
| Clever Leaves | 0.00% | Reduce −15.5% | 1,629,363 | $0.2025 | $330K | −298,582 | −$406K |
Showing top 50 of 110 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2023 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Horizon Therapeutics Pub L | 3.35% | Exit | 0 | $109.14 | $592M | −5,419,823 | −$592M |
| Shaw Communications · CL B | 2.68% | Exit | 0 | $29.92 | $473M | −15,800,000 | −$473M |
| DT - Dynatrace | 1.86% | Exit | 0 | $42.30 | $329M | −7,788,269 | −$329M |
| Oak Str Health | 0.99% | Exit | 0 | $38.68 | $174M | −4,503,076 | −$174M |
| Prometheus Biosciences | 0.67% | Exit | 0 | $107.32 | $118M | −1,100,806 | −$118M |
| Holding · CL A | 0.16% | Exit | 0 | $10.15 | $29M | −2,809,000 | −$29M |
| Metals Acquisition · CL A | 0.14% | Exit | 0 | $10.22 | $25M | −2,489,700 | −$25M |
| JAZZ - Jazz Pharmaceuticals | 0.12% | Exit | 0 | $146.33 | $22M | −150,000 | −$22M |
| Maxar Technologies | 0.12% | Exit | 0 | $51.06 | $20M | −400,000 | −$20M |
| Syneos Health · CL A | 0.10% | Exit | 0 | $35.62 | $17M | −472,000 | −$17M |
| AVTR - Avantor | 0.08% | Exit | 0 | $21.14 | $14M | −681,418 | −$14M |
| Holding · CLASS A | 0.08% | Exit | 0 | $10.22 | $14M | −1,360,040 | −$14M |
| Tcv Acquisition · CL A | 0.07% | Exit | 0 | $10.24 | $12M | −1,211,459 | −$12M |
| Broadmark Rlty Cap | 0.06% | Exit | 0 | $4.70 | $11M | −2,437,995 | −$11M |
| Tpg Pace Beneficial Ii | 0.06% | Exit | 0 | $9.97 | $11M | −1,116,833 | −$11M |
| Churchill Capital Vii · CL A | 0.06% | Exit | 0 | $10.14 | $10M | −1,000,000 | −$10M |
| Churchill Capital Vi · CL A | 0.06% | Exit | 0 | $10.11 | $10M | −997,767 | −$10M |
| Holding · CL A | 0.05% | Exit | 0 | $10.50 | $9M | −900,000 | −$9M |
| Holding | 0.05% | Exit | 0 | $10.12 | $9M | −848,184 | −$9M |
| Holding · CL A | 0.04% | Exit | 0 | $10.25 | $8M | −750,000 | −$8M |
| Panacea Acquisition Ii · CL A | 0.04% | Exit | 0 | $10.20 | $8M | −750,000 | −$8M |
| Khosla Ventures Acquisition · CL A | 0.04% | Exit | 0 | $10.14 | $7M | −700,000 | −$7M |
| Rcf Acquisition · CL A | 0.04% | Exit | 0 | $10.46 | $6M | −600,000 | −$6M |
| Tio Tech A · CLASS A | 0.03% | Exit | 0 | $10.18 | $5M | −502,001 | −$5M |
| Lamf Global Ventures I · CLASS A | 0.02% | Exit | 0 | $10.45 | $4M | −400,000 | −$4M |
| Holding · CLASS A | 0.02% | Exit | 0 | $10.37 | $4M | −350,000 | −$4M |
| Sound Point Acquisition · CLASS A | 0.02% | Exit | 0 | $10.55 | $3M | −300,000 | −$3M |
| NUVB - Nuvation Bio · CL A | 0.01% | Exit | 0 | $1.66 | $2M | −1,465,000 | −$2M |
| Provention Bio | 0.01% | Exit | 0 | $24.10 | $2M | −90,000 | −$2M |
| NTRS - Northern Trust · CL A | 0.01% | Exit | 0 | $10.07 | $1M | −100,000 | −$1M |
| Amyris | 0.01% | Exit | 0 | $1.36 | $961K | −706,700 | −$961K |
| Legend Biotech | — | Exit | 0 | $48.24 | $849K | −17,600 | −$849K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2